Strategic Partners ( ) - 株価, ニュースと分析DB:1TB0

1TB0 株式概要

ストラテジック・パートナーズA/Sは重要な業務を行っていない。

1TB0 ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

報酬

過去5年間の収益は年間42.7%増加しました。

リスク分析

意味のある時価総額がありません ( €40M )

収益が 100 万ドル未満 ( DKK0 )

過去3か月間の株価の変動は非常に激しい

過去1年間で株主の希薄化が進んだ

Strategic Partners A/S 競合他社

4SC

DB:VSC

€61.5m

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€24.3m

価格と性能

の歴代最高値、変動、値下がりまとめStrategic Partners
過去の株価
現在の株価	DKK 137.50
52週高値	DKK 181.50
52週安値	DKK 89.50
ベータ	0.079
11ヶ月の変化	-7.41%
3ヶ月変化	27.31%
1年変化	28.75%
33年間の変化	-96.14%
5年間の変化	-97.94%
IPOからの変化	-97.76%

Recent updates

株主還元

	1TB0	DE Biotechs	DE 市場
7D	-7.4%	-3.1%	-1.0%
1Y	28.7%	-15.2%	16.1%

業界別リターン: 1TB0過去 1 年間で-15.2 % の収益を上げたGerman Biotechs業界を上回りました。

リターン対市場: 1TB0過去 1 年間で16.1 % の収益を上げたGerman市場を上回りました。

価格変動

Is 1TB0's price volatile compared to industry and market?
1TB0 volatility
1TB0 Average Weekly Movement	12.3%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

安定した株価: 1TB0の株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: 1TB0の weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2009	1	Jakob Bendtsen	www.strategic-partners.dk

Strategic Partners A/Sは重要な事業を行っていない。以前は神経変性希少疾患の治療薬の開発に従事していた。以前はOrphazyme A/Sとして知られていたが、2024年10月にStrategic Partners A/Sに社名変更した。同社は2009年に法人化され、デンマークのヘレフを拠点としている。

Strategic Partners A/S 基礎のまとめ

Strategic Partners の収益と売上を時価総額と比較するとどうか。
1TB0 基礎統計学
時価総額	€5.30m
収益（TTM）	-€1.53m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-3.5x

PER（株価収益率

1TB0 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
1TB0 損益計算書（TTM）
収益	DKK 0
売上原価	DKK 0
売上総利益	DKK 0
その他の費用	DKK 11.42m
収益	-DKK 11.42m

直近の収益報告

Jun 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-273.69
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

1TB0 の長期的なパフォーマンスは？

過去の実績と比較を見る

1TB0 株式概要

報酬

リスク分析

Strategic Partners A/S 競合他社

DB:VSC

€61.5m

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€24.3m

価格と性能

最新ニュース

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Recent updates

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: €10.56

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: €7.41

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: €8.67

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

New 90-day low: €9.92

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low - €11.52